






Malignancy is a major risk factor for developing venous thromboembolism (VTE), and thus cancer 
patients are at high risk for deep vein thrombosis (DVT) and/or pulmonary embolism (PE). While 
the guideline-recommended anticoagulant for the treatment of cancer-associated VTE is low-
molecular-weight heparin (LMWH), direct oral anticoagulants (DOAC) such as rivaroxaban and 
apixaban are often prescribed for various reasons including patient preference, convenience, and 
cost. The purpose of this study was to retrospectively assess the appropriateness of rivaroxaban 
and apixaban dose as well as rate of VTE recurrence and bleeding outcomes in patients with 




From April 2014 to April 2016, adults aged over 18 years old diagnosed with cancer (ICD-9 codes 
140. to 239.) and prescribed rivaroxaban or apixaban in both inpatient and outpatient settings 
for the treatment DVT and/or PE were included in this study. Among additional exclusions, 
subjects excluded had a concomitant diagnosis of atrial fibrillation/flutter and were on treatment 
for less than six months. From the time of initiation to up to six months, each subject’s chart was 
reviewed to assess potential need for dosage adjustment or any unindicated dosage adjustments. 
Any recurrent VTE events or bleeding events from the time of initiation to up to six months were 




Of 82 subjects assessed, an inappropriate initial dose was prescribed in 26 subjects and 24 
subjects for rivaroxaban and apixaban respectively. During the six months after initiation, no 
other dosage-adjustments occurred nor were any warranted. Rivaroxaban patients had a lower 
rate of VTE recurrence but a higher rate of major bleeding at six months than in other published 
studies. Apixaban patients had a lower rate of both VTE recurrence as well as major bleeding and 




Despite guideline recommendations, some providers prescribe rivaroxaban or apixaban for 
cancer-associated VTE. Our analysis demonstrated that both rivaroxaban and apixaban are often 
initially dosed inappropriately and dose adjustment for renal or hepatic dysfunction or drug 
interactions is commonly disregarded. Future analyses of this dataset will compare these 






Malignancy is a hypercoagulable state that leads to a four to seven-fold increased risk for VTE
1
. 
A population study at Olmsted County, Minnesota showed that cancer presented a fourfold 
increased risk of VTE (odds ratio (OR) 4.1, 95% CI: 1.9-8.5)
2
. In the United Kingdom, a cohort study 
using Cancer Registry data linked to Hospital Episode Statistics found a relative risk (RR) of VTE 
of 4.7 in cancer patients (95% CI: 4.5-4.9)
3
. It is estimated that four to twenty percent of patients 
with cancer will experience a cancer-related thrombosis (CAT) event
4
. Moreover, in cancer, VTE 
and thrombotic complications are the second most frequent cause of mortality and these 




The hypercoagulable state in cancer is a complex interdependent mechanism involving 
interactions among cancer cells, host cells, and the coagulation system
1
. Tumor cells are thought 
to have the ability to activate the coagulation system and interact with hematopoietic cells, thus 
altering the balance between endogenous coagulants and anticoagulants
1
. Specifically, factors 
that contribute to the prothrombotic state in cancer are also the same characteristics that 
contribute to tumor progression
1
. These factors include the production by tumor of 
microparticles, proangiogenic factors, inflammatory cytokines, and tumor cell adhesion 
molecules that bind platelets and leukocytes
1
. As a result, increased clot formation and activation 
of coagulation eventually lead to thrombotic vascular events. Venous manifestation of CAT 
includes DVT, PE, or visceral vein thrombosis. Arterial manifestation includes stroke or 
myocardial infarction. 
 
Risk factors for CAT can be characterized into three main categories: patient-dependent, tumor-
related, or treatment-related. According to the Registry of Patients with Venous 
Thromboembolism (RIETE) investigators, women were found to have a lower rate of DVT 
recurrences (HR 0.78, 95% CI: 0.67-0.91) but a higher mortality due to PE (HR 1.24, 95% CI: 1.04-
1.47) when compared to men
5
. Other patient-specific factors include older age, race, 
comorbidities such as obesity, diabetes, previous VTE, and decreased performance status
1
. In 
addition, hematologic malignancies and distant metastatic disease were found to have a higher 
rate of thrombosis events compared to local cancer diseases, a 10.3% VTE incidence compared 
to 5.6% in localized disease in a multicenter retrospective study of hospitalized cancer patients 
(RR 1.92, 95% CI: 1.21-3.04)
6
. Furthermore, chemotherapy has been linked to a two- to six-fold 
increase in VTE occurrence
2
. Other treatment-related factors include use of central venous 





Cancer patients with initial VTE may require extended anticoagulant therapy, though the optimal 
duration is not fully elucidated. According to the American Society of Clinical Oncology (ASCO) 
and the National Comprehensive Cancer Network (NCCN), routine outpatient 
thromboprophylaxis is not recommended
7,8
. Thromboprophylaxis throughout hospitalization is 
recommended and patients undergo major cancer surgery should receive prophylaxis starting 
before surgery and continuing up to four weeks post-operation
7,8
. The risk of recurrence VTE in 




. In addition, a few risk assessment scores are available to help predict the risk of CAT, 
although they are not commonly utilized in thromboprophylaxis evaluation. For instance, NCCN 
and ASCO panel recommend the use of a validated tool called Khorana Score to differentiate 
between high- and low-risk patients
7,8
. This risk score was originated from a development cohort 
of 1,365 patients from a prospective registry and externally validated by the Vienna CATS 
consortium and other retrospective cohort studies
9
. The following table lists the current 
recommendations from major oncology guidelines regarding antithrombotic therapies for acute 
VTE as well as duration for long-term anticoagulants. 
 
Table 1: Major Guidelines Acute VTE Treatment and Duration Recommendations 
 
 Acute VTE Long-term Anticoagulation Duration 
ASCO7 
(2014) 
LMWH preferred over 
UFH for initial 5-10 days 
of treatment 
LMWH preferred over VKA, 
with VKA as acceptable 
alternative 
 
DOACs not recommended 
At least 6 months 
NCCN8 
(2016) 
LMWH, UFH, or 
fondaparinux 
LMWH preferred over VKA, 
with VKA as acceptable 
alternative 
 
DOACs not recommended 
Minimum 3 months to 
indefinitely in patients 




Not addressed  LMWH over VKA and DOACs, 
with no preference to VKA 
 
DOACs if LMWH is not used 
Continue same agent for 
the first 3 months 
ITAC-CME11 
(2016) 
LMWH is preferred over 
UHF and fondaparinux  
LMWH preferred over VKAs 
 
DOACs can be considered for 
VTE treatment of patients with 
stable cancer not receiving 
systemic anticancer therapy 
Minimum of 3 months 
ACCP = American College of Chest Physicians, ITAC-CME = International Initiative on Thrombosis and Cancer, VKA = Vitamin-K 
antagonist 
 
LMWH is recommended as first-line for VTE treatment through findings from the Low Molecular 
Weight Heparin Versus Oral Anticoagulant Therapy for Long Term Anticoagulation in Cancer 
Patients with Venous Thromboembolism (CLOT)
12
 trial in 2003. In this study, LMWH (dalteparin) 
was shown to be superior to warfarin in term of recurrent VTE rate reduction at 6 months without 
statistically significant difference in the rate of bleeding or mortality
12
. In 2015, the Comparison 
of Acute Treatments in Cancer Hemostasis (CATCH)
13
 trial was conducted to further support 
recommendations for LMWH use in CAT. However, the study failed to detect significant 
difference in VTE recurrence after 6 months
13
. This was attributed to a “healthier” patient 
population with fewer VTE risk factors such as higher performance status, less metastatic disease, 
less systemic anticancer treatment, and less extensive history of thrombosis.  
 5 
When compared to warfarin, DOACs have favorable profile in term of drug-drug interaction, 
dosing convenience, and no required therapeutic drug monitoring. The CHEST 2016 Guideline 
recommends DOACs over warfarin for the treatment of VTE in non-cancer patients
14
. Landmark 
trials for DOACs have established efficacy and safety in this population. Specifically, rivaroxaban 
was compared to enoxaparin and warfarin in the EINSTEIN-DVT and EINSTEIN-PE trials
15
. 
Apixaban was compared to enoxaparin and warfarin in the AMPLIFY trial
16
. The following table 
summarizes the pharmacokinetics and pharmacodynamics of DOACs. 
 










Approval Date 2010 2011 2012 2015 
Drug Class Direct 
thrombin 
inhibitor 
Factor Xa inhibitor 
Half-life 12-17 hrs 5-9 hrs 12 hrs 10-14 hrs 
Metabolism P-gp, 
hydrolysis 




Remains mostly as 






66% of total dose 
(36% as unchanged 
drug) 
27% of total 
dose 
50% of total dose 
Food Effects May be taken 
with or 
without food 
10-mg tablet may be 
taken with/without food 
 
15-mg and 20-mg 
tablets should be taken 
with the largest meal of 
the day 
Bioavailability 
not affected by 
food 
Can be administered 
without regard to 
food 
VTE Dosing 10 mg daily x7 
days, then 5 
mg BID 
15 mg BID x21 days, 
then 20 mg daily 
10 mg daily x7 
days, then 5 mg 
BID 
60 mg daily 




CrCl < 30 
ml/min: avoid 
CrCl <30 ml/min: avoid CrCl < 15 
ml/min: avoid 
CrCl 15-50 ml/min: 
30 mg daily 







Avoid in Child-Pugh 
Class B/C 
Avoid in Child-
Pugh Class C 
Avoid in Child-Pugh 
Class B/C 
CrCl = Creatinine clearance 
 
While the guideline-recommended anticoagulant for the treatment of cancer-associated VTE is 
LMWH
21
, DOACs are often prescribed off-labeled for various reasons including patient 
preference, convenience, and cost. There are pending trials aiming to assess efficacy and safety 
of DOACs for VTE treatment in cancer patients. Results of the first of such trials involved 
 6 
edoxaban’s and was published late 2017. The authors of this study concluded that oral edoxaban 
was non-inferior to subcutaneous dalteparin with respect to the composite outcome of recurrent 
VTE or major bleeding. However, the rate of major bleeding was higher with edoxaban
22
. In 
addition, a recent meta-analysis suggests DOACs are comparable to vitamin K antagonists (VKA) 
for preventing VTE recurrence and bleeding events in cancer patients
23





The objective of this study is to retrospectively assess the appropriateness of dose as well 
as efficacy and safety of rivaroxaban and apixaban in patients with cancer-related VTE 
treatment at UNC Medical Center.  
Study Design: 
This is a non-interventional, retrospective study in patients initiated with rivaroxaban or 
apixaban for the treatment of cancer-related VTE. 
 
Study Endpoints 
The primary endpoints of this study include appropriateness of rivaroxaban and apixaban 
dose for VTE treatment, recurrent of VTE and bleeding outcomes at 6 months. 
Study Population  
a. Inclusion criteria:  
§ At least 18 years old diagnosed with cancer (ICD-9 codes 140.xx to 239.xx)  
§ Prescribed rivaroxaban (April 2014 – October 2015) or apixaban (April 2014 – April 
2016) for VTE treatment at UNC Medical Center  
b. Exclusion criteria: 
§ Treated with rivaroxaban or apixaban for less than 6 months 
§ Had concomitant atrial fibrillation or flutter 
§ Had VTE prior to cancer diagnosis 
§ Diagnosed clotting disorder 
§ Benign cancerous lesion 
§ Failed treatment with a different anticoagulant prior to rivaroxaban or apixaban 
initiation  
§ Lost to follow-up 
 
Statistical Methods 
a. Study size: Given the solely descriptive nature of the study objectives, the sample size 
was not based on formal statistical hypothesis testing. Sample size was planned to be 
approximately 35 to 50 patients where all patients who met eligibility criteria would 
be included in the analysis. 
b. Main summary measurements: Descriptive statistics (percent, means, medians, 
range, standard deviations) were used to describe patient demographic/clinical 




Of all 1,576 rivaroxaban orders from April 2014 to October 2015, 192 subjects had ICD-9 codes 
from 140. to 239. Further exclusion based on benign lesions, on therapy prior to study dates, lost 
to follow up, or on therapy for less than six months resulted in 50 subjects eligible for data 
analysis. Of all 1,813 apixaban orders from April 2014 to April 2016, 1,585 were excluded based 
on ICD-9 codes having benign lesions, atrial fibrillation, or unknown. Additional 196 subjects 
further excluded based on all remaining exclusion criteria, resulting in 32 eligible subjects for data 
analysis.  
 
Respectively of rivaroxaban and apixaban, the study population was comprised predominantly of 
white (64% and 81%) females (60% and 53%) with a mean age of 57.9 and 67.3 years old. About 
one third patients of each group are obese. The majority of patients had hematologic cancers, 
Child-Pugh Class A, and normal renal function. Some patients’ data were not available for renal 
and hepatic function assessment based upon lab availability at UNC Medical Center within two 
months of initiation. Among rivaroxaban patients, one patient was on both aspirin 81 mg and 
NSAID around-the-clock. Among apixaban patients, two patients had CrCl less than 25 ml/min.  
 
Table 3: Baseline Characteristics 
 
Patient Characteristics Rivaroxaban (n = 50) Apixaban (n = 32) 
Age (years), mean (range) 57.9 (19-89) 67.3 (40-88) 
Female, n (%) 30 (60) 17 (53) 
BMI > 30 kg/m
2
, n (%) 17 (34) 10 (31) 
Race 
African American, n (%) 
White or Caucasian, n (%) 










DVT only, n (%) 
PE only, n (%) 









Active Chemotherapy, n (%) 22 (46%) 13 (38%) 
CrCl (ml/min) 
< 30, n (%) 
30-60, n (%) 
> 60, n (%) 











Child-Pugh Class  
Class A, n (%) 
Class B, n (%) 
Class C, n (%) 













Aspirin, n (%) 
P2Y12 Inhibitor, n (%) 
NSAID (ATC), n (%) 
















Hematology/Oncology, n (%) 
Surgery, n (%) 









ATC = around the clock, DDI = drug-drug interaction, NSAID = nonsteroidal anti-inflammatory agent, PRN = as needed. 
 
Figure 1: Types of Cancer 
 
*Others include connective tissue and brain cancers 
 
In term of appropriateness of dose, for rivaroxaban, twenty-six (52%) patients were initially 
prescribed inappropriate doses. At time of initiation, seven (14%) patients were inappropriately 
prescribed based on contraindications (DDI with itraconazole, renal and hepatic dysfunction). 
After 21 days, seven (14%) patients were not appropriately dose-reduced to 20 mg by mouth 
(PO) daily. After initiation, one patient had a potential DDI identified with fluconazole; however, 
the dose was not adjusted. During the six months, no other dosage-adjustments occurred. The 
following graph illustrates reasons for inappropriate initial apixaban dose 
 




For apixaban, twenty-four (75%) patients were initially prescribed inappropriate doses; however, 
none of these patients had contraindications to therapy. After 7 days, all patients were 
appropriately dose-reduced to 5 mg PO twice daily. After initiation, one patient was dose-
adjusted from 5 mg PO daily to 2.5 mg PO daily due to sign of bleeding (bruising). During the six 
months, no other dosage-adjustments occurred. The following graph illustrates reasons for 
inappropriate initial rivaroxaban dose 
 




In addition, rivaroxaban VTE recurrence and major bleeding rates at 6 months are 6.3% and 12.5% 
respectively. Apixaban VTE recurrence and major bleeding rates at 6 months are 2.9% and 5.9% 
respectively.  The following tables list the rates from major clinical trials for rivaroxaban 
(EINSTEIN PE/DVT) and apixaban (AMPLIFY) VTE treatment.   
 
Table 4: Outcomes at 6 months for Rivaroxaban Patients  
 
Study Drug 6 Month VTE Recurrence 6 Month Major Bleeding 
Our Study (n = 50) Rivaroxaban 6.3% 12.5% 
EINSTEIN PE/DVT  
(n = 354)
15 
Rivaroxaban 4.5% 2.3% 
CLOT (n = 336)
12 
Dalteparin 8.0% 5.6% 
CLOT (n = 336)
12 
Warfarin 15.8% 3.6% 
CATCH (n = 449)
13 
Tinzaparin 6.9% 2.7% 
 
Table 5: Outcomes at 6 months for Apixaban Patients  
 
Study Drug 6 Month VTE Recurrence 6 Month Bleeding* 
Our study (n = 32) Apixaban 2.9% 5.9% 
AMPLIFY (n = 534)
16 
Apixaban 1.9% 8.1% 
AMPLIFY (n = 534)
16 
Warfarin 6.3% 17.4% 
CLOT (n = 336)
12 
Warfarin 15.8% 19% 
CLOT (n = 336)
12 
Dalteparin 8% 14% 





Our analysis demonstrated that both initial and maintenance doses of rivaroxaban and apixaban 
are often inappropriately selected. A majority of rivaroxaban patients were initiated on 20 mg 
PO daily despite the correct VTE treatment dose is 15 mg PO twice daily for 21 days and then 20 
mg PO once daily. In the same manner, the majority of apixaban patients were initiated on 5 mg 
PO twice daily despite the correct VTE treatment dose is 10 mg PO twice daily for 7 days and then 
5 mg PO twice daily. Apixaban dosing for VTE treatment may be mistaken with dosing for stroke 
prevention in non-valvular atrial fibrillation (NVAF), which is 5 mg PO twice daily. Moreover, 
rivaroxaban was inappropriately prescribed in six patients with Child-Pugh Class B or impaired 
renal function (CrCl less than 30 ml/min). In contrast, no patients receiving apixaban had 
documented impaired hepatic. Two patients with CrCl less than 25 ml/min were initiated on 
apixaban. According to apixaban prescribing information, CrCl less than 15 ml/min is 
contraindicated. However, in the AMPLIFY study, subjects were excluded if having CrCl less than 
25 ml/min. This was an interesting pattern observed in our apixaban cohort. In addition, no 
patients were inappropriately dose-adjusted during the six-month follow-up period as well as no 
adjustments warranted. One apixaban patient was dose-reduced from 5 mg PO daily to 2.5 mg 
PO daily due to signs of bleeding and this adjustment was subjective to the provider as no 
literatures or guidelines recommend on dosing adjustment due to sign of bleeding for VTE 
treatment.  
 
Among patients receiving rivaroxaban, the risk of VTE recurrence in our cohort was lower 
however major bleeding rate was higher than in other published studies. Patients being actively 
treated with chemotherapy may be at a particular high risk of bleeding. In addition, among 
patients receiving apixaban, both the risk of VTE recurrence and bleeding, including major 
bleeding and clinically relevant non-major bleeding rates in our cohort were lower than in other 
published studies. Further characterization of bleeding events and bleeding rates in this dataset 
is forthcoming to better understand cofounders or risk factors contributing to a higher rate of 




Despite not being guideline recommended for cancer-associated VTE, rivaroxaban and apixaban 
continue to be frequently prescribed. Our study showed that initial and maintenance doses are 
often prescribed inappropriately and despite of contraindication to therapy. The primary 
limitation of this study included small sample size, single center, and retrospective design. The 
latter precluded inquiry of providers to identify intention for alternative DOAC dosing strategies. 
Future analyses of this data will compare these subjects’ outcomes, such as recurrent VTE and 





Potential Implications and Future Direction 
 
This study was the first to examine the appropriateness of dose and outcomes of DOACs for 
cancer-related VTE treatment at UNC Medical Center. Due to the nature of retrospective design 
as discussed in our limitation, we were unable to further explain the observed dosing difference 
from the manufacturer’s recommendation. However, this study’s finding provides potential 
opportunities for provider education on appropriate VTE treatment dosing. In addition, we 
developed our inclusion and exclusion criteria with the purpose of minimizing confounders that 
might interfere with interpretation of outcomes and appropriateness of dose. In the future, we 
would like to collect platelet counts because providers may not initiate patients on a full 
anticoagulant dose due to a low baseline platelet. In addition, as discussed in the background 
section, we would also like to collect cancer treatment regimen as some chemotherapy put a 
patient at a higher risk of developing VTE. Overall, future direction will aim to identify and assess 
potential risk factors or baseline characteristics that put patients at a higher risk of having 
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